San Francisco, CA, United States of America

Arvind Rajpal

This inventor holds 46 USPTO granted patents and 35 published patent applications, plus 12 CIPO patents and 17 EPO patents, primarily in Therapeutic Antibodies. Top assignees: Pfizer Corporation, Bristol-Myers Squibb Compnay, Rinat Neuroscience Corporation. Active years: 2011-2026.

USPTO Granted Patents = 46 (Patent Applications = 35)

% Patents Active = 80.4

CIPO Patents = 12 (Patent Applications = 19)

EPO Patents = 17 (Patent Applications = 43)

Average Co-Inventor Count = 7.8

ph-index = 11

Forward Citations = 409(Granted Patents)

Location History:

Chesterfield, MO (US) (2011)
San Francisco, CA (US) (2011 - 2024)

Company Filing History:

Bristol-Myers Squibb Compnay

patents

14 out of 53

Rinat Neuroscience Corporation

patents

4. 5 out of 77

Five Prime Therapeutics, Inc.

Allogene Therapeutics, Inc.

patents

where one patent can have more than one assignee

Years Active: 2011-2026

Loading Chart...

Areas of Expertise:

Therapeutic Antibodies

Chimeric Antigen Receptors

Anti-PD-1

Antibody-Drug Conjugates

Binding Molecules

Universal Antibody Libraries

Prodruggable Antibodies

Heterodimeric Proteins

Nucleic Acids

Cancer Immunotherapy

VISTA Binding Antibodies

Modified Heavy Constant Regions

46 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12624124 - HETERODIMERIC PROTEINS AND METHODS FOR PRODUCING AND PURIFYING THEM (2026-05-12),

2. 12478674 - IPILIMUMAB VARIANTS WITH ENHANCED SPECIFICITY FOR BINDING AT LOW PH (2025-11-25),

3. 12195535 - Antibodies binding to VISTA at acidic pH (2025-01-14),

4. 12173069 - Antibodies binding to vista at acidic pH (2024-12-24),

5. 12091462 - Antibodies binding to vista at acidic pH (2024-09-17),

6. 11912776 - Chimeric antigen receptors targeting B-cell maturation antigen (2024-02-27),

7. 11814435 - Therapeutic antibodies and their uses (2023-11-14),

8. 11674240 - Universal antibody libraries (2023-06-13),

9. 11623965 - Prodruggable antibodies, prodrugs thereof, and methods of use and making (2023-04-11),

10. 11603406 - Antibodies binding to VISTA at acidic pH (2023-03-14),

11. 11602525 - Antibody-drug conjugates with high drug loading (2023-03-14),

12. 11390689 - Heterodimeric proteins and methods for producing and purifying them (2022-07-19),

13. 11338035 - Anti-PD-1 antibodies and methods of use thereof (2022-05-24),

14. 11312782 - Chimeric antigen receptors targeting B-cell maturation antigen (2022-04-26),

15. 11306150 - Method of identifying a P-selectin glycoprotein ligand-1 (PSGL-1) antagonist (2022-04-19),

Title: Innovator Spotlight: Arvind Rajpal's Cutting-Edge Patent Portfolio

Introduction:

Arvind Rajpal, a prolific inventor based in San Francisco, CA, has been making waves in the field of biotechnology with his groundbreaking patents. With an impressive total of 41 patents to his name, Rajpal is at the forefront of innovation in the healthcare sector.

Latest Patents:

Rajpal's most recent patents demonstrate his expertise in developing advanced therapeutics targeting specific antigens. One notable invention is the Chimeric Antigen Receptors (CARs) targeting B-cell maturation antigen. This technology focuses on engineered immune cells that can effectively combat conditions associated with malignant cells expressing BCMA, such as cancer.

Another significant patent is related to therapeutic antibodies and their uses. Rajpal's invention revolves around antibodies that bind to BCMA and CD3, offering potential treatments for cancer and autoimmune diseases. The development of antibody conjugates and heteromultimeric antibodies further showcases his innovative approach to diagnostics and therapeutics.

Career Highlights:

Throughout his career, Arvind Rajpal has made substantial contributions to renowned companies in the industry. Notable among his affiliations are Pfizer Corporation and Rinat Neuroscience Corporation, where he has brought his expertise to the forefront of cutting-edge research and development.

Collaborations:

Rajpal's success is also attributed to his collaborations with like-minded professionals in the field. Notable coworkers such as Pavel Strop and Haichun Huang have played key roles in advancing his innovative projects and bringing his ideas to fruition.

Conclusion:

Arvind Rajpal's patent portfolio reflects his unwavering commitment to pushing the boundaries of biotechnological innovation. Through his groundbreaking work in developing targeted therapeutics and antibodies, Rajpal continues to be a driving force in revolutionizing healthcare treatments.